New therapeutic possibilities for vein graft disease in the post-edifoligide era

Future Cardiology

Volumn 2, Issue 4, 2006, Pages 493-501

  Cai, Xinjiang ^a   Freedman, Neil J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cell cyle inhibition; Coronary artery bypass grafting; Coronary heart disease; E2F decoy; Neointimal hyperplasia; Vascular smooth muscle cells; Vein graft disease

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; ACETYLSALICYLIC ACID; AGL 2033; AGL 2043; ANGIOTENSIN II; ANTILIPEMIC AGENT; DOUBLE STRANDED DNA; EDIFOLIGIDE; FK 506 BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOLOGIC AGENT; INTERCELLULAR ADHESION MOLECULE 1; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; QUINOXALINE DERIVATIVE; RAPAMYCIN; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN 165;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DNA SYNTHESIS INHIBITION; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG TARGETING; EX VIVO STUDY; GRAFT FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LEG ISCHEMIA; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RESTENOSIS; REVIEW; STEM CELL; TREATMENT FAILURE; VASCULAR SMOOTH MUSCLE; VEIN GRAFT; VEIN GRAFT DISEASE;

EID: 33747710761     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.4.493     Document Type: Review

References (78)

1. Thom T, Haase N, Rosamond W et al.: Heart Disease and Stroke Statistics-2006 Update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113, E85-E151 (2006).
2. Simosa HF, Conte MS: Genetic therapy for vein bypass graft disease: current perspectives. Vascular 12, 213-217 (2004).
3. Halabi AR, Alexander JH, Shaw LK et al.: Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. Am. J. Cardiol. 96, 1254-1259 (2005).
4. Motwani JG, Topol EJ: Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97, 916-931 (1998).
5. Goldman S, Copeland J, Moritz T et al.: Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. Circulation 80, 1190-1197 (1989).
6. Desai ND, Cohen EA, Naylor CD, Fremes SE: A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N. Engl. J. Med. 351, 2302-2309 (2004).
7. Alexander JH, Hafley G, Harrington RA et al.: Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled vial. JAMA 294, 2446-54 (2005).
8. Mohler ER 3rd: Peripheral arterial disease: identification and implications. Arch. Intern. Med. 163, 2306-2314 (2003).
9. Stary HC, Blankenhorn DH, Chandler AB et al.: A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 85, 391-405 (1992).
10. Conte MS, Bandyk DF, Clowes AW et al.: Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J. Vasc. Surg. 43, 742-751 (2006).
11. Goldman S, Copeland J, Moritz T et al.: Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 77, 1324-1332 (1988).
12. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257, 3233-3240 (1987).
13. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH: Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 264, 3013-3017 (1990).
14. Avila PC, Campeau L, Knatterud GL, Domanski M, Hunninghake DB: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N. Engl. J. Med. 336, 153-163 (1997).
15. Ehsan A, Mann MJ, Dell'Acqua G, Tamura K, Braun-Dullaeus R, Dzau VJ: Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease. Circulation 105, 1686-1692 (2002).
16. Owens GK, Kumar MS, Wamhoff BR: Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84, 767-801 (2004).
17. Mann MJ, Gibbons GH, Kernoff RS et al.: Genetic engineering of vein grafts resistant to atherosclerosis. Proc. Natl Acad. Sci. USA 92, 4502-4506 (1995).
18. Zhang L, Freedman NJ, Brian L, Peppel K: Graft-extrinsic cells predominate in vein graft arterialization. Arterioscler. Thromb. Vasc. Biol. 24, 470-476 (2004).
19. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ: Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J. Thorac. Cardiovasc. Surg. 121, 714-722 (2001).
20. Berk BC: Vascular smooth muscle growth: autocrine growth mechanisms. Physiol. Rev. 81, 999-1030 (2001).
21. Yang Z, Oemar BS, Carrel T, Kipfer B, Julmy F, Luscher TF: Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation 97, 181-187 (1998).
22. Hu Y, Zou Y, Dietrich H, Wick G, Xu Q: Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin. Circulation 100, 861-868 (1999).
23. Davies MG, Owens EL, Mason DP et al.: Effect of platelet-derived growth factor receptor-α and -β blockade on flow-induced neointimal formation in endothelialized baboon vascular grafts. Circ. Res. 86, 779-786 (2000).
24. Peppel K, Jacobson A, Huang X, Murray JP, Oppermann M, Freedman NJ: Overexpression of G protein-coupled receptor kinase-2 in smooth muscle cells attenuates mitogenic signaling via G protein-coupled and platelet-derived growth factor receptors. Circulation 102, 793-799 (2000).
25. Peppel K, Zhang L, Huynh TT et al.: Overexpression of G protein-coupled receptor kinase-2 in smooth muscle cells reduces neointimal hyperplasia. J. Mol. Cell Cardiol. 34, 1399-1409 (2002).
26. Fulton GJ, Davies MG, Barber L, Svendsen E, Hagen PO: Localized versus systemic angiotensin II receptor inhibition of intimal hyperplasia in experimental vein grafts by the specific angiotensin II receptor inhibitor L158,809. Surgery 123, 218-227 (1998).
27. Davies MG, Fulton GJ, Barber L, Dalen H, Svendsen E, Hagen PO: Characterisation of angiotensin II receptor mediated responses and inhibition of intimal hyperplasia in experimental vein grafts by the specific angiotensin II receptor inhibitor, L158,809. Eur. J. Vasc. Endovasc. Surg. 12, 151-161 (1996).
28. O'Donohoe MK, Davies MG, Radic ZS, Mikat EM, Hagen PO: Increased concentrations of angiotensin-converting enzyme in the intimal hyperplasia of experimental vein grafts. J. Cardiovasc. Pharmacol. 23, 594-601 (1994).
29. O'Donohoe MK, Schwartz LB, Radic ZS, Mikat EM, McCann RL, Hagen PO: Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts. Ann. Surg. 214, 727-732 (1991).
30. Peppel K, Zhang L, Orman ES et al.: Activation of vascular smooth muscle cells by TNF and PDGF: overlapping and complementary signal transduction mechanisms. Cardiovasc. Res. 65, 674-682 (2005).
31. Zhang L, Peppel K, Brian L, Chien L, Freedman NJ: Vein graft neointimal hyperplasia is exacerbated by tumor necrosis factor receptor-1 signaling in graft-intrinsic cells. Arterioscler. Thromb. Vasc. Biol. 24, 2277-2283 (2004).
32. Hu Y, Mayr M, Metzler B, Erdel M, Davison F, Xu Q: Both donor and recipient origins of smooth muscle cells in vein graft atherosclerotic lesions. Circ. Res. 91, E13-E20 (2002).
33. Cooley BC: Murine model of neointimal formation and stenosis in vein grafts. Arterioscler. Thromb. Vasc. Biol. 24, 1180-1185 (2004).
34. Zhang L, Hagen PO, Kisslo J, Peppel K, Freedman NJ: Neointimal hyperplasia rapidly reaches steady state in a novel murine vein graft model. J. Vasc. Surg. 36, 824-832 (2002).
35. Tomas JJ, Stark VE, Kim JL et al.: X-galactosidase-tagged adventitial myofibroblasts tracked to the neointima in healing rat vein grafts. J. Vasc. Res. 40, 266-275 (2003).
36. Shi Y, O'Brien JE Jr, Mannion JD et al.: Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation 95, 2684-2693 (1997).
37. Liu C, Nath KA, Katusic ZS, Caplice NM: Smooth muscle progenitor cells in vascular disease. Trends Cardiovasc. Med. 14, 288-293 (2004).
38. Sata M, Saiura A, Kunisato A et al.: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med. 8, 403-409 (2002).
39. Wolff RA, Tomas JJ, Hullett DA, Stark VE, van Rooijen N, Hoch JR: Macrophage depletion reduces monocyte chemotactic protein-1 and transforming growth factor-β1 in healing rat vein grafts. J. Vasc. Surg. 39, 878-888 (2004).
40. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005).
41. Zou Y, Hu Y, Mayr M, Dietrich H, Wick G, Xu Q: Reduced neointima hyperplasia of vein bypass grafts in intercellular adhesion molecule-1-deficient mice. Circ. Res. 86, 434-440. (2000).
42. Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R: Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl. Acad. Sci. USA 102, 18111-18116 (2005).
43. Walter DH, Haendeler J, Reinhold J et al.: Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ. Res. 97, 1142-1151 (2005).
44. Chavakis E, Aicher A, Heeschen C et al.: Role of β2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J. Exp. Med. 201, 63-72 (2005).
45. Stevens C, La Thangue NB: E2F and cell cycle control: a double-edged sword. Arch. Biochem. Biophys. 412, 157-169 (2003).
46. Mann MJ, Whittemore AD, Donaldson MC et al.: Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354, 1493-1498 (1999).
47. Morishita R, Gibbons GH, Horiuchi M et al.: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl Acad. Sci. USA 92, 5855-5859 (1995).
48. Grube E: Project of ex vivo vein graft engineering via transfection (PREVENT) II trial. Presented at: The Annual American Heart Association Scientific Sessions. Anaheim, California, 11-14 November 2001.
49. Costa MA, Simon DI: Molecular basis of restenosis and drug-eluting stents. Circulation 111, 2257-2273 (2005).
50. Woods TC, Marks AR: Drug-eluting stents. Annu. Rev. Med. 55, 169-178 (2004).
51. Hausleiter J, Kastrati A, Mehilli J et al.: Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the oral sirolimus to inhibit recurrent in-stent stenosis (OSIRIS) trial. Circulation 110, 790-795 (2004).
52. Fukuda D, Sata M, Tanaka K, Nagai R: Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 111, 926-931 (2005).
53. Ge L, Iakovou I, Sangiorgi GM et al.: Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J. Am. Coll. Cardiol. 45, 989-994 (2005).
54. Schachner T, Zou Y, Oberhuber A et al.: Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann. Thorac. Surg. 77, 1580-1585 (2004).
55. Masaki T, Rathi R, Zentner G et al.: Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int. 66, 2061-2069 (2004).
56. Raines EW: PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 15, 237-254 (2004).
57. Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79, 1283-1316 (1999).
58. Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J: LRP: role in vascular wall integrity and protection from atherosclerosis. Science 300, 329-332 (2003).
59. Ross R: Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
60. Sano H, Sudo T, Yokode M et al.: Functional blockade of platelet-derived growth factor receptor-β but not of receptor-α prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 103, 2955-2960 (2001).
61. Hart CE, Kraiss LW, vergel S et al.: PDGFβ receptor blockade inhibits intimal hyperplasia in the baboon. Circulation 99, 564-569 (1999).
62. O'Brien SG, Guilhot F, Larson RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003).
63. Levitzki A: PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc. Res. 65, 581-586 (2005).
64. Banai S, Chorny M, Gertz SD et al.: Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials 26, 451-461 (2005).
65. Myllarniemi M, Frosen J, Calderon Ramirez LG, Buchdunger E, Lemstrom K, Hayry P: Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc. Drugs Ther. 13, 159-168 (1999).
66. Lassila M, Allen TJ, Cao Z et al.: Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24, 935-942 (2004).
67. Zohlnhofer D, Hausleiter J, Kastrati A et al.: A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. J. Am. Coll. Cardiol. 46, 1999-2003 (2005).
68. West NE, Qian H, Guzik TJ et al.: Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production. Circulation 104, 1526-1532 (2001).
69. -/- mice is related to decreased endothelial progenitor cell repair. Circ. Res. 98, 412-420 (2006).
70. Mann MJ, Gibbons GH, Tsao PS et al.: Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J. Clin. Invest. 99, 1295-1301 (1997).
71. Shintani T, Sawa Y, Takahashi T et al.: Intraoperative transfection of vein grafts with the NFκB decoy in a canine aortocoronary bypass model: a strategy to attenuate intimal hyperplasia. Ann. Thorac. Surg. 74, 1132-1138 (2002).
72. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
73. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA: In vivo activity of nuclease-resistant siRNAs. RNA 10, 766-771 (2004).
74. Walker T, Wendel HP, Tetzloff L, Heidenreich O, Ziemer G: Suppression of ICAM-1 in human venous endothelial cells by small interfering RNAs. Eur. J. Cardiothorac. Surg. 28, 816-820 (2005).
75. Lazar HL: Role of statin therapy in the coronary bypass patient Ann. Thorac. Surg. 78, 730-740 (2004).
76. Yamanouchi D, Banno H, Nakayama M et al.: Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. J. Vasc. Surg. 42, 757-764 (2005).
77. Ali ZA, Bursill CA, Hu Y et al.: Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice. Circulation 112, 1235-1241 (2005).
78. Mann MJ: Transcription factor decoys: a new model for disease intervention. Ann. N. Y Acad. Sci. 1058, 128-139 (2005).